Both of these cover the use of the company’s Covid-19 vaccine in development. In this case, NVX-CoV2373 was able to meet the endpoints of both the Phase 3 PREVENT-19 trial and Study 307 tests.
The data from the PREVENT-19 trial shows that Novavax’s Covid-19 vaccine was effective at increasing antibody levels as a booster in already vaccinated adults. It was also effective against the omicron BA.1, BA.2 and BA.5 variants.
In addition to that, PREVENT-19 was expanded to include pediatric patients between 12 and 17 years old. Yet again, the vaccine was found effective as a booster and for combating Covid-19 variants.
NVAX Stock and Study 307 Results
Study 307 covers “lot consistency” of the NVX-CoV2373 vaccine. The results were positive with consistent responses seen in patients ages 18 to 49 years. Anti-S IgG titers were also consistent with data from the PREVENT-19 clinical trial. Finally, safety results were consistent across lots.
It doesn’t stop there, however. While the data shows that Novavax’s vaccine is effective as a booster, it could also treat more variants of Covid-19. The company is currently testing the vaccine against the BA.4/5 variants and intends to share that data in the future.
NVAX stock is down slightly as of Wednesday morning.
Investors seeking out more of the hottest stock market news are in luck!
InvestorPlace has them covered with all of the latest stock stories for Wednesday! Among that is what has shares of PepsiCo (NASDAQ:PEP) stock rising, what has Bed Bath & Beyond (NASDAQ:BBBY) moving and this morning’s biggest pre-market stock movers. You can find all of that at the following links!
More Wednesday Stock Market News
- Why Is Pepsi (PEP) Stock Up Today?
- Why Is Bed Bath & Beyond (BBBY) Stock Climbing Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.